Qube (QUB) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting held in hybrid format, allowing both in-person and online participation, with voting and Q&A accessible to all shareholders and proxy holders.
Notice of meeting, agenda, and voting instructions were distributed electronically and via mail, and all materials were lodged with the ASX.
Introduction of board members, management, and auditor, with special welcome to new directors John Beavan and Mick McCormack.
Managing Director presented an overview of the company's performance and strategic direction.
Financial performance review
Underlying revenue reached $4,461.4m, up 27.3% on FY24, with underlying EBITA up 18.5%.
Underlying NPATA increased by 6.2% to $288.0m, and underlying EPSA rose 6% to AUD 0.1625.
EBITA margin (excluding grain trading) improved to 10.5%, up 1.0% on FY24, reflecting productivity improvements.
Group ROACE improved to 9.9%, up 0.4% on FY24.
Most business segments delivered higher revenue and earnings, with strong performance in Energy and Agri-related activities.
Board and executive committee updates
Jackie McArthur resigned; John Beavan and Mick McCormack joined the board and stood for election.
Jill Hoffmann to chair the Nomination and Remuneration Committee; Steve Mann to join the committee.
Allan Davies announced his retirement as chair, with John Beavan elected as successor.
Leadership focused on safety culture, operational leverage, and disciplined investment.
Latest events from Qube
- Strong H1 FY26 growth and a $5.20/share takeover offer mark a transformative period.QUB
H1 202620 Feb 2026 - Double-digit earnings and EPSA growth, with continued expansion and resilient outlook.QUB
H2 202423 Jan 2026 - Double-digit growth, higher dividends, and improved safety defined a robust FY24.QUB
AGM 202413 Jan 2026 - H1 FY25 revenue up 28.4%, EBITA up 14%, with at least 5% NPATA growth expected for FY25.QUB
H1 202521 Dec 2025 - Record revenue, margin gains, and strong outlook, despite MITCO JV impairment.QUB
H2 202523 Nov 2025